Zhang F, Wang W, Hou X, et al. - Treatment of type 2 diabetes using ertugliflozin (a novel sodium–glucose cotransporter inhibitor) not only provides an effective reduction of glycated hemoglobin levels but also affords extra clinical advantages including bodyweight and fasting plasma glucose.

• A meta-analysis of 10 randomized controlled trials with 13,223 patients to test ertugliflozin, vs placebo or other antihyperglycemic agents, for type 2 diabetes.

• Ertugliflozin 5 mg and 15 mg provided weighted mean differences in glycated hemoglobin of −0.77% and −0.82%, respectively, vs a placebo.

• Bodyweight loss (weighted mean difference −1.87 kg) was also observed with ertugliflozin 5 mg daily.

• Significant reduction in fasting plasma glucose by −1.62 mmol/L was afforded by ertugliflozin vs placebo.

• Yet, an increasing risk for genital mycotic infections was noted (risk ratio 4.34).

• Similar results were observed for the 15 mg ertugliflozin.